objectives Diagnosis of pleural tuberculosis (PT) is still a challenge, particularly in resourceconstrained settings. Alternative diagnostic tools are needed. We aimed at evaluating the utility of Clinical Prediction Rules (CPRs) for diagnosis of pleural tuberculosis in Peru.
Introduction
Diagnosis of pleural tuberculosis (PT) is a challenge, particularly in resource-constrained settings. The occurrence of pleural exudates raises clinical suspicion of this condition and patients' pleural fluids are usually evaluated for the presence of acid-fast bacilli (AFB) through ZiehlNeelsen staining, for malignant cells through haematoxylin-eosin staining and through Gram examination for common bacteria. However, in a large proportion of cases, these tests do not lead to a diagnosis, amongst others because the presence of the tuberculous bacilli in pleural fluid specimens is scarce. Additionally, the diagnostic contribution of molecular techniques, when available, is only modest [1] . Invasive procedures, such as closed pleural biopsy and thoracoscopy, are then recommended. These can establish the diagnosis in most cases, but come at the risk of complications, require high-level expertise and equipment and have an elevated cost [2] .
Clinical prediction rules (CPRs), or 'scores', have been developed to contribute to the diagnosis of PT. They combine several clinical signs or symptoms and/or laboratory tests as predictors and could inform clinical decision-making [3] . However, they need to be locally validated before implementation. This validation is usually performed through the evaluation of the standard indicators of diagnostic performance (sensitivity, specificity, predictive values and areas under the ROC curve (AUC)) against a reference diagnostic standard.
Meanwhile, the diagnostic utility of Adenosine deaminase activity (ADA) for PT continues to be controversial, but some recent publications support its use [4, 5] . It has been advocated as helpful in low-to-medium incidence settings [6] , although not considered in the clinical guidelines of these countries [7] . In contrast, it is included in guidelines for diagnosis of PT in high-incidence Latin American countries [8] . Its utility, compared to that of CPRs, has still to be evaluated.
Our aim was to identify existing CPRs for the diagnosis of PT, to determine their performance in patients with pleural exudates in Peru and to evaluate their clinical utility in relation to ADA.
Materials and methods

Identification of the CPRs for the diagnosis of PT
We performed literature searches in MEDLINE and LILACs to retrieve CPRs for PT. For the MEDLINE search, we followed the procedures suggested by Ingui et al., prioritising sensitivity [9] with some modifications and adding the Mesh terms related to 'tuberculosis' and to 'pleural', both as MeSh terms and as text. We manually searched the 'related articles' displayed in PubMed and the references of the selected retrieved papers for additional CPRs. Two researchers (LS and AS), screened the abstracts of the retrieved papers and independently selected the publications on CPRs to be included. Discrepancies were solved by consensus. The inclusion criteria were as follows: Clinical Prediction Rules (defined as a combination of signs, symptoms and laboratory tests that jointly interpreted lead to a clinical decision) [10] and having PT as an outcome to be predicted. We excluded from subsequent evaluation CPRs derived for specific groups, such as children, HIV positive or inmuno-compromised patients. We also excluded CPRs that included as predictive findings 'high-complexity tests' as defined by the FDA 0 s CLIA (clinical laboratory improvement amendments) [11] . These are, amongst others, molecular methods, interferon-gamma release assays, lysozyme determinations and antibody tests for M. tuberculosis, which are not normally available in hospital laboratories, even at referral level, in low-middle income countries.
Setting, patients and clinical procedures
We performed the validation of the CPRs in patients attending Hospital Nacional Cayetano Heredia and Hospital Nacional Hipolito Unanue, third-level hospitals in Lima, Peru, a Latin American country with a concentrated HIV epidemic and a high incidence (120/10 5 ) of tuberculosis. The sample size needed was calculated based on 90% power to detect an increase of 10% in the overall accuracy of the evaluated CPRs compared to ADA determination, for which we assumed a baseline accuracy of 75%. Allowing for 10% of non-evaluable cases, the required number of participants was 190.
From October 2009 to February 2012, all new adult patients that attended the internal medicine wards of these hospitals and had pleural effusion according to chest X-ray or ultrasound were screened with Light's criteria [12] for distinguishing between exudates and transudates. Patients with exudates were referred to the neumology units for inclusion in the study.
After giving informed consent, demographic and clinical information was collected through direct interviews and physical examination. Mycobacterial culture in Lowenstein-Jensen media and papanicolaou was performed on sputum samples of all patients. Pleural aspirates were obtained, and patients with hemothorax or grossly turbid empyemas were excluded from further study, as their management required therapeutic surgical procedures rather than diagnosis. Pleural fluid specimens were sent for determination of cell count and differential, glucose, lactate dehidrogenase, protein, ADA, ZiehlNeelsen staining, cultures for mycobacteria in Ogawa and Mycobacterial Growth Indicator Tube (MGIT) media, PCR for M. tuberculosis and cytology for malignant cells. Trained neumologists performed on all patients a closed pleural biopsy with Abrams needle according to standard procedures [13] , and the pleural tissue was sent for histopathological examination by certified pathologists and for culture in MGIT if tissue quantity sufficed. Specific complementary tests performed when indicated included culture in Sabouread media for fungal infections and immunohistochemistry for connective tissue diseases amongst others. All laboratory results were promptly communicated to the treating physicians, who remained in charge for the subsequent management of the patients.
Diagnostic classification
We classified the patients into four diagnostic categories:
• Pleural Tuberculosis: our reference standard was positive AFB smear or positivity for M. tuberculosis in any of the culture media or positive PCR for M. tuberculosis in pleural fluid or tissue; or presence of caseating granulomas in the histopathology; or compatible histopathological results (lymphocytic infiltration, unspecific granulomas, fibrosis) followed by resolution of the effusion and symptoms within the 3 months after initiation of antituberculous therapy.
• Malignant pleural exudate: the presence of malignant cells in the pleural fluid or biopsy
• Other specific pleurisies (connective tissue diseases, fungal infections and other conditions diagnosed through histopathology or specific complementary tests).
• Pleural exudate of unknown cause: patients for whom no definite diagnosis could be established.
Data analysis
Each withheld CPR was applied to every patient. For CPRs derived to differentiate PT from other conditions, the diagnostic categories 'malignant pleural effusion' and 'other specific pleurisies' were jointly considered 'Not PT'. For CPRs designed to differentiate PT from malignant pleural exudates, the diagnostic category 'other causes' were excluded from the analysis.
In both situations, patients with two coexisting aetiologies for the pleural exudate and those with pleural exudates of unknown cause were excluded from the analysis.
We compared the results obtained through the CPRs with our reference standard for PT to calculate their sensitivity, specificity, predictive values, likelihood ratios and, for the CPRs based on scoring systems, the areas under their ROC curve (AUC)s. We did the same for ADA at two different cut-off levels: 40 and 60 UI/L. All statistical analyses were performed with STATA ver. 10.
Ethical aspects
All included patients gave written informed consent for participation. The ethics committees of Universidad Peruana Cayetano Heredia, Hospital Nacional Cayetano Heredia, Hospital Nacional Hipolito Unanue and the Institute of Tropical Medicine, Antwerp approved the study.
Results
Identified CPRs
We retrieved 2419 publications using our MEDLINE search strategy and 280 through the LILACs search ( Figure 1 ). This yielded 25 CPRs and three additional ones were found through the revision of the references. Of these, 11 CPRs including one neural network were excluded because they considered 'high-complexity' test amongst their predictive findings, including one neural network. Despite the study being performed at two thirdlevel hospitals, our laboratories were not equipped to perform C-reactive protein test (CRP), complement activation products dosage and pleural globulin level determination, all classified as moderate complexity tests by the FDA-CLIA. Neither could we perform the TST on all patients. For this reason, we could not assess five eligible CPRs [14] [15] [16] [17] [18] . Figure 1 resumes the procedure of selection of the CPRs. Table 1 summarises the main characteristics of the 12 CPRs we evaluated [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Many of them had been derived in study populations with high incidences of PT. The most common predictors included were ADA (in 11 CPRs), lymphocyte proportion (in 7), protein in pleural fluid (in 4) and age (in 6).
Patient characteristics
We evaluated 383 patients for inclusion. Of these, 101 (26.4%) did not consent to participate in the study, five were lost to follow-up, 12 (3.1%) had pus in the thoracentesis and in three the procedures of thoracentesis or pleural biopsy failed. Finally, 262 patients had a complete workup.
Out of them, 176 (67.2%) had PT,140 had microbiological or histopathological confirmation and 36 showed histopathological signs suggestive of PT and complete resolution of symptoms in response to treatment. Fifty patients had malignant pleural effusion, 12 had other specific pleurisies such as rheumatoid or fungal pleuritis, three had concomitant evidence of PT and malignant pleuritis and 21 (8.1%) had pleural exudates of unknown cause (Figure 2 ). Table 2 compares demographic, clinical and laboratory findings between patients with PT and not PT (malignant pleural effusion and other specific pleuritis). Younger age, male gender, former contact with a patient with tuberculosis, shorter duration of illness, fever, night sweats and high ADA and protein levels in pleural fluid were positively associated with PT.
Accuracy of the CPRs
The sensitivity, specificity, predictive values and likelihood ratios for the diagnosis of PT of each of the evaluated CPRs are shown in Table 3 . In general, the sensitivities of the CPRs were substantially lower in our setting than reported in the original papers, but the specificities were comparable. While the CPRs designed for diagnosis of PT attained low sensitivities, Melo's and Neves's had a specificity of 100% and together with Dheda's, and Demirer's, attained positive likelihood ratios above 10. CPRs for differentiation with cancer had higher sensitivities but did not attain negative likelihood ratios lower than 0.10. Given the high PT prevalence in our patients, all CPRs attained high-positive predictive values (90-100%), but all had negative predictive values below 70%. ADA alone had the highest overall diagnostic accuracy for diagnosis of TP at a cut-off point of 40 UI/L (87% for diagnosis of PT), with a sensitivity of 86% (95% CI 81-91) and a specificity of 87% (95% CI 77-93) ( Table 4) differentiation between PT and cancer respectively. These were not significantly different from the AUC for ADA (0.89, CI 0.81-0.95).
Discussion
We validated 12 clinical prediction rules (CPRs) for diagnosis of pleural tuberculosis (PT), most of them derived during the last decade in countries with moderate or high incidence of tuberculosis. Our validation series consisted of patients with pleural exudates, among whom the prevalence of PT was 67%, not surprising for a country with a high tuberculosis burden. Some CPRs had very high specificity but due to their low-to-moderate sensitivity, attained only modest overall accuracy (the highest at 86%). The Adenosine Deaminase (ADA) test on its own performed the best according this diagnostic indicator (87%), due to its better sensitivity and acceptable specificity (86% and 87% respectively). CPRs added to what was already achieved by ADA only in terms of specificity, strengthening the positive likelihood for diagnosis of PT, but detracting on sensitivity.
Our results constitute the first formal validation of a set of CPRs for PT, most of which had not been previously externally validated. We found, as expected, that they perform less well than in the setting they were developed. This is common to all kinds of CPRs and is the reason why it is important to perform their local validation before application.
We expressly chose not to include CPRs with 'highcomplexity tests' among their predictive findings, because is against the nature of CPRs to use such tests and, more importantly, because facilities that can perform them are not common in most high-incidence countries. Still, research on interferon-gamma release assays (IGRAs) tests in pleural fluid show promising results [31] for diagnosis of TP if combined with other biomarkers. This is because in isolation it has important limitations: a recent meta-analysis of 14 studies shows a pooled sensitivity of 72% and a pooled specificity of 78% for the diagnosis of PT [32] . The assessment of other specific markers of inflammation due to M. tuberculosis may prove increasingly useful, in line with the physiopathology of pleural tuberculosis.
However, molecular techniques intended to capture the presence of bacilli, which are scarce in PT, have low sensitivity [33] and could, at best, be used if and when available. Other CPRs excluded used lysozyme, antibodies for M. tuberculosis or citoquines that are definitively of too high complexity for use in resource-constrained settings or at peripheral level.
A limitation of this study was that we were not able to validate five CPRs that included tests of moderate complexity, which could not be performed at our tertiary level hospitals due to laboratory constraints. These tests were C-reactive protein, complement activation products, globulin levels in pleural fluid, and TST. The latter test is a marker of tuberculosis infection, with fluctuating availability globally, and would probably not be useful in a setting where more than 50% of the population is positive [34] . As C-reactive protein is intended to discriminate PT from bacterial infections, which were not present in our patient series, it would have scarcely contributed. A similar situation occurs with pleural globulins and complement activation products. While pleural globulins have been associated with TP [35] , other infectious conditions such as pneumonia and some neoplastic disorders like multiple myeloma can significantly raise the level of globulins in the pleural fluid and currently the trend is to study the nature of the globulins rather than to assess them it as a whole [36] . Complement activation products are most of all useful for diagnosis of lupus and other connective tissue diseases, when low levels are found, and less so for TP or cancer diagnosis [37] . The lack of diagnostic thoracoscopy could also be of concern. Twenty-one (8.1%) patients remained without definite diagnosis after pleural biopsy and these patients are, according to current recommendations [38] , candidates for thoracoscopy. Notwithstanding, our rate of undiagnosis is similar to the rate of around 10% reported in the literature [39] . Finally, of the few patients with empyema that we excluded from analysis, some could have been tuberculous pleuritis cases. However, diagnosing PT in the presence of purulent fluid poses no major diagnostic challenge, as AFB are generally found [40] . At any rate, empyema calls for surgical intervention. Above all, this study adds evidence on the utility of ADA in the diagnostic approach of TP. Currently, only Latin American guidelines consider its use as part of diagnostic recommendations. An explanation may be that, compared to other forms of extrapulmonary tuberculosis, pleural tissue is relatively accessible and that clinicians often chose to confirm PT through histopathological examination. However, in countries with high incidence of tuberculosis, considerable amounts of resources could be saved and risks avoided with the use of ADA as a decisionmaking tool. Surprisingly, clinical prediction rules do not or hardly perform better than ADA alone for diagnosis of PT. Designing CPRs intended to improve on what ADA already discriminates would be an interesting development. In resource-constrained settings, where ADA determination is not available, Dheda's CPR, the only evaluated not including ADA as a predictive finding, could be an option, despite its moderate (74%) overall diagnostic accuracy.
In conclusion, we assessed the performance of published CPRs for the diagnosis of PT in a country with high incidence of tuberculosis. We found that they do not contribute significantly over ADA alone in overall diagnostic performance, although some of them improve the specificity. ADA, an inexpensive, simple and accessible test, shows a good diagnostic performance and is an important element in the diagnostic approach to PT. 
